Henry Schein (HSIC) Projected to Release Earnings on Tuesday

Key Points

• Henry Schein is expected to report Q3 2026 earnings before the market opens on November 3. Analysts project earnings of $1.36 per share on $3.48 billion in revenue, compared with full-year EPS guidance of $5.29–$5.39.
• The company exceeded expectations in its most recent quarter, reporting $1.27 EPS versus the $1.24 consensus and $3.46 billion in revenue, up 6.7% year over year.
• Analysts remain generally positive on HSIC, with a “Moderate Buy” consensus rating and a $93.27 average price target; the stock recently traded at $84.51.

Henry Schein (NASDAQ:HSIC - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Henry Schein to announce earnings of $1.36 per share and revenue of $3.48 billion for the quarter. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Investors can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating analysts' consensus estimates of $1.24 by $0.03. The company had revenue of $3.46 billion for the quarter, compared to analysts' expectations of $3.37 billion. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%. The business's revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.10 earnings per share. On average, analysts expect Henry Schein to post $5.36 EPS for the current fiscal year and $5.94 EPS for the next fiscal year.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $84.51 on Tuesday. Henry Schein has a 12-month low of $62.15 and a 12-month high of $92.18. The company has a market cap of $9.42 billion, a PE ratio of 24.64, a P/E/G ratio of 1.53 and a beta of 0.84. The stock has a 50 day simple moving average of $86.85 and a 200-day simple moving average of $80.94. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60.

Analyst Ratings Changes

A number of research analysts have issued reports on HSIC shares. Barrington Research set a $104.00 price target on Henry Schein in a research report on Wednesday, August 5th. Piper Sandler raised their price target on Henry Schein from $91.00 to $95.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Stifel Nicolaus set a $95.00 price objective on shares of Henry Schein in a research note on Wednesday, August 5th. Citigroup reaffirmed a "buy" rating and issued a $112.00 price objective (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. Finally, BTIG Research upped their price objective on shares of Henry Schein from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, August 19th. Nine analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $93.27.

Henry Schein Company Profile

Henry Schein, Inc NASDAQ: HSIC is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.